Startseite Desmopressin administration in children with central diabetes insipidus: a retrospective review
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Desmopressin administration in children with central diabetes insipidus: a retrospective review

  • Hooi Leng Ooi EMAIL logo , Ann M. Maguire und Geoffrey R. Ambler
Veröffentlicht/Copyright: 11. Juli 2013

Abstract

Background: Central diabetes insipidus (DI) is a rare disorder in children caused by a deficiency of antidiuretic hormone arginine (vasopressin). Desmopressin is the first line agent in management of central DI. However, one of the side effects of desmopressin is water intoxication and hyponatraemia. This study reviews the patterns of desmopressin use and side effects in our institution.

Methods: Retrospective chart review of all patients with central DI followed up in one tertiary centre between 1 January 2008 and 31 December 2010.

Results: Forty-one patients (22 males and 19 females) were included. Twelve patients (29.3%) had congenital and 29 patients (70.7%) had acquired DI, mostly as a result of intracranial tumours. Thirty-six (87.8%) patients were on oral desmopressin and the remaining on nasal formulation. The median oral dose was 9.5 (4.2–17.0) μg/kg/day with median frequency of 2.5 (2–3). The median nasal dose was 0.7 (0.4–1.4) μg/kg/day with median frequency of 2.0 (2–3.5). Fourteen patients (34.1%) were switched from nasal to oral desmopressin with the median dose conversion factor of 20.1 (10.7–31.8). Forty percent of patients on nasal desmopressin experienced hypo/hypernatraemia compared to 18.1% on oral, however, there were no significance difference between standardized hypo/hypernatraemia episodes per treatment year.

Conclusions: Oral desmopressin is used in the majority of our patients including infants and toddlers. There is wide inter-individual variation in dose requirement and dosing intervals. Management of central diabetes insipidus remains a challenge in adipsic patients and in young children during intercurrent illness regardless of the desmopressin formulation.


Corresponding author: Hooi Leng Ooi, Institute of Endocrinology and Diabetes, The Children’s Hospital at Westmead, Westmead, NSW 2145, Sydney, Australia, Phone: +61 2 9845 3200, Fax: +61 2 9845 3170, E-mail:

This research was approved by the Sydney Children’s Hospitals Network Human Research Ethics Committee.

References

1. Maghnie M, Cosi G, Genovese E, Manca-Bitti ML, Cohen A, et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000;343:998–1007.10.1056/NEJM200010053431403Suche in Google Scholar PubMed

2. Westgren U, Wittstrom C, Harris AS. Oral desmopressin in central diabetes insipidus. Arch Dis Child 1986;61:247–50.10.1136/adc.61.3.247Suche in Google Scholar PubMed PubMed Central

3. Mishra G, Chandrashekhar SR. Management of diabetes insipidus in children. Indian J Endocrinol Metab 2011; 15(Suppl 3):180–7.10.4103/2230-8210.84858Suche in Google Scholar PubMed PubMed Central

4. Kim RJ, Malattia C, Allen M, Moshang T Jr, Maghnie M. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations. Pediatr Endocrinol Rev 2004;2(Suppl 1):115–23.Suche in Google Scholar

5. Di Iorgi N, Napoli F, Allegri AE, Olivieri I, Bertelli E, et al. Diabetes insipidus–diagnosis and management. Horm Res Paediatr 2012;77:69–84.10.1159/000336333Suche in Google Scholar PubMed

6. Williams TD, Dunger DB, Lyon CC, Lewis RJ, Taylor F, et al. Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-D-arginine vasopressin. 1. Studies in adults and children. J Clin Endocrinol Metab 1986;63:129–32.10.1210/jcem-63-1-129Suche in Google Scholar PubMed

7. Vande Walle J, Stockner M, Raes A, Norgaard JP. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2007;2:232–8.10.2174/157488607781668891Suche in Google Scholar PubMed

8. Robson WL, Leung AK, Norgaard JP. The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol 2007;178:24–30.10.1016/j.juro.2007.03.015Suche in Google Scholar PubMed

9. Toumba M, Stanhope R. Morbidity and mortality associated with vasopressin analogue treatment. J Pediatr Endocrinol Metab 2006;19:197–201.10.1515/JPEM.2006.19.3.197Suche in Google Scholar PubMed

10. Greger NG, Kirkland RT, Clayton GW, Kirkland JL. Central diabetes insipidus. 22 years’ experience. Am J Dis Child 1986;140:551–4.10.1001/archpedi.1986.02140200061028Suche in Google Scholar PubMed

11. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002;246: 1–190.Suche in Google Scholar

12. Fjellestad A, Czernichow P. Central diabetes insipidus in children. V. Oral treatment with a vasopressin hormone analogue (DDAVP). Acta Paediatr Scand 1986;75: 605–10.10.1111/j.1651-2227.1986.tb10259.xSuche in Google Scholar PubMed

13. Rittig S, Jensen AR, Jensen KT, Pedersen EB. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf) 1998;48:235–41.10.1046/j.1365-2265.1998.00340.xSuche in Google Scholar

14. Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf) 1993;38:177–82.10.1111/j.1365-2265.1993.tb00990.xSuche in Google Scholar

15. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985;103:228–39.10.7326/0003-4819-103-2-228Suche in Google Scholar

16. Fjellestad A, Rappaport R, Czernichow P. Oral treatment of central diabetes insipidus (DI) in children by DDAVP tablets. Pediatr Res 1985;19:604.10.1203/00006450-198506000-00027Suche in Google Scholar

17. Stick SM, Betts PR. Oral desmopressin in neonatal diabetes insipidus. Arch Dis Child 1987;62:1177–8.10.1136/adc.62.11.1177Suche in Google Scholar

18. Adverse Drug Reactions Advisory Committee (ADRAC) and the Adverse Drug Reactions Unit (ADRU) of the TGA. Desmopressin and hyponatraemia. Aust Adv Drug Reactions Bull 2008;27:15.Suche in Google Scholar

19. Fjellestad-Paulsen A, Tubiana-Rufi N, Harris A, Czernichow P. Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin. Acta Endocrinol (Copenh) 1987;115:307–12.10.1530/acta.0.1150307Suche in Google Scholar

20. Fukuda I, Hizuka N, Takano K. Oral DDAVP is a good alternative therapy for patients with central diabetes insipidus: experience of five-year treatment. Endocr J 2003;50:437–43.10.1507/endocrj.50.437Suche in Google Scholar

21. Murphy I. Minirin dose equivalence. In: Chin C, editor. Pymble, Australia: Ferring Pharmaceuticals, 2003.Suche in Google Scholar

22. Thumfart J, Roehr CC, Kapelari K, Querfeld U, Eggert P, et al. Desmopressin associated symptomatic hyponatremic hypervolemia in children. Are there predictive factors? J Urol 2005;174:294–8.Suche in Google Scholar

23. Argenti D, Ireland D, Heald DL. A pharmacokinetic and pharmacodynamic comparison of desmopressin administered as whole, chewed and crushed tablets, and as an oral solution. J Urol 2001;165:1446–51.10.1016/S0022-5347(05)66325-2Suche in Google Scholar

24. Blanco EJ, Lane AH, Aijaz N, Blumberg D, Wilson TA. Use of subcutaneous DDAVP in infants with central diabetes insipidus. J Pediatr Endocrinol Metab 2006;19:919–25.10.1515/JPEM.2006.19.7.919Suche in Google Scholar PubMed

25. Rivkees SA, Dunbar N, Wilson TA. The management of central diabetes insipidus in infancy: desmopressin, low renal solute load formula, thiazide diuretics. J Pediatr Endocrinol Metab 2007;20:459–69.10.1515/JPEM.2007.20.4.459Suche in Google Scholar PubMed

26. Ball SG, Vaidja B, Baylis PH. Hypothalamic adipsic syndrome: diagnosis and management. Clin Endocrinol (Oxf) 1997;47:405–9.10.1046/j.1365-2265.1997.2591079.xSuche in Google Scholar PubMed

27. Crowley RK, Sherlock M, Agha A, Smith D, Thompson CJ. Clinical insights into adipsic diabetes insipidus: a large case series. Clin Endocrinol (Oxf) 2007;66:475–82.10.1111/j.1365-2265.2007.02754.xSuche in Google Scholar PubMed

Received: 2013-2-27
Accepted: 2013-6-5
Published Online: 2013-07-11
Published in Print: 2013-11-01

©2013 by Walter de Gruyter Berlin Boston

Artikel in diesem Heft

  1. Masthead
  2. Masthead
  3. Review article
  4. Application of imaging modalities for evaluating neuroblastoma
  5. Images in pediatric endocrinology
  6. Lingual thyroid
  7. Original articles
  8. A levothyroxine dose recommendation for the treatment of children and adolescents with autoimmune thyroiditis induced hypothyroidism
  9. Fasting glucagon-like peptide-1 in patients with overt hyperthyroidism and euthyroid congenital hypothyroidism
  10. Perinatal complications and higher risks of offspring thyroid dysfunction in early childhood of Graves’ disease mothers with euthyroidism
  11. Clinical characteristics and management of cranial diabetes insipidus in infants
  12. Desmopressin administration in children with central diabetes insipidus: a retrospective review
  13. An electronic surveillance system for monitoring the hospital presentation of nutritional vitamin D deficiency in children in Scotland
  14. Frequency and severity of ketoacidosis at onset of autoimmune type 1 diabetes over the past decade in children referred to a tertiary paediatric care centre: potential impact of a national programme highlighted
  15. Vitamin D status is associated with early markers of cardiovascular disease in prepubertal children
  16. Evaluation of bone mineral density in children with type 1 diabetes mellitus
  17. Observational study of diabetes management in type 1 diabetic school-age children during holiday versus school days
  18. Relationship of body mass index and GAD65 antibody status on β-cell secretion at diabetes onset in African-American children
  19. Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus
  20. Concomitant autoantibodies in newly diagnosed diabetic children with transient celiac serology or proven celiac disease
  21. Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey
  22. Cognitive impairment and gray/white matter volume abnormalities in pediatric patients with Turner syndrome presenting with various karyotypes
  23. Prevalence of metabolic syndrome among urban Indian adolescents and its relation with insulin resistance (HOMA-IR)
  24. Prevalence of metabolic syndrome in obese Chilean children and association with gene variants of the leptin-melanocortin system
  25. Evaluation of serum neopterin levels and its relationship with adipokines in pediatric obesity-related nonalcoholic fatty liver disease and healthy adolescents
  26. Could GSD type I expand the spectrum of disorders with elevated plasma chitotriosidase activity?
  27. Patient reports
  28. Treatment of hyperinsulinemic hypoglycemia because of diffuse nesidioblastosis with nifedipine after surgical therapies in a newborn
  29. Successful subcutaneous glucagon use for persistent hypoglycaemia in congenital hyperinsulinism
  30. A novel atypical presentation of insulin autoimmune syndrome (Hirata’s disease) in a child
  31. Diagnosis of septo-optic dysplasia in a neonate with hypernatremia, hypoglycemia, and persistent hypothermia
  32. Speech and language delay in two children: an unusual presentation of hyperthyroidism
  33. Lissencephaly presenting with congenital hypothyroidism
  34. PHEX gene mutation in a Chinese family with six cases of X-linked hypophosphatemic rickets
  35. Primary hyperparathyroidism as an extremely rare cause of secondary myelofibrosis in childhood
  36. A family with Camurati-Engelman disease: the role of the missense p.R218C mutation in TGFbeta1 in bones and endocrine glands
  37. A case of SCNN1A splicing mutation presenting as mild systemic pseudohypoaldosteronism type 1
  38. Central precocious puberty in a girl with Prader-Willi syndrome
  39. Type 1 diabetes mellitus in a patient with homozygous sickle cell anemia
  40. Short communication
  41. No impact of obesity susceptibility loci on weight regain after a lifestyle intervention in overweight children
  42. Letter to the Editor
  43. Reliability and validity of homeostasis model assessment for insulin resistance and β-cell dysfunction in critically ill children with hyperglycemia
Heruntergeladen am 2.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2013-0078/html
Button zum nach oben scrollen